We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients?

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2010 by Ziv Hospital.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01146626
First Posted: June 17, 2010
Last Update Posted: April 28, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Hillel Yaffe Medical Center
Information provided by:
Ziv Hospital
  Purpose

Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 80% of naïve patients with genotype 2,3. Studies rarely address the issues of improving host factors. The current study examines

  1. whether adding vitamin D, a potent immunomodulator, could improve viral response and shorten treatment duration (from 24 weeks to 12 weeks)
  2. whether Vitamin D levels predictes negative treatment outcome.

Condition Intervention
Hepatitis C Drug: Peg+ Vitamin D+ Ribavirine Drug: Peg+ Ribavirine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Does Vitamin D Supplement Improve SVR in Chronic Hepatitis C (Genotype 2,3) in naïve Patients Treated With Peginterferon Alpha and Ribavirin

Resource links provided by NLM:


Further study details as provided by Ziv Hospital:

Primary Outcome Measures:
  • SVR rate [ Time Frame: 1 year ]
    to evaluate the response rate


Estimated Enrollment: 60
Study Start Date: August 2011
Estimated Study Completion Date: May 2012
Estimated Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Peg+ Vitamin D+ Ribavirine
Peg+ Vitamin D+ Ribavirine
Drug: Peg+ Vitamin D+ Ribavirine
Peg+ Vitamin D+ Ribavirine
Experimental: Peg+ Ribavirine
Peg+ Ribavirine
Drug: Peg+ Ribavirine
Peg+ Ribavirine

Detailed Description:
Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 80% of naïve patients with genotype 2,3. Studies rarely address the issues of improving host factors. The current study examines whether adding vitamin D, a potent immunomodulator, could improve viral respons.The working hypothesis is that Adding vitamin D to conventional Peg/RBV therapy for naïve, genotype 2,3 patients with chronic HCV infection significantly improves RVR, EVR, and SVR
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 to 65 years of age,
  • Chronic genotype 2,3 HCV infection, Traetment Naive
  • Negative sero for HBV, HDV and HIV viral infections
  • Absolute neutrophil count of >1500 per cubic millimeter, a platelet count of >90,000 per cubic millimeter
  • Normal hemoglobin level

Exclusion Criteria:

  • Decompensated liver disease (cirrhosis with CP score >9)
  • Another cause of clinically significant liver disease
  • Hepato cellular carcinoma
  • Psychiatric Disorder
  • Chronic heart failure
  • Pregnant women
  • Uncontrolled diabetes with retinopathy
  • Arythmia
  • Active CAD
  • Positive sero for HBV, HDV and HIV viral infections or other autoimmune liver disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01146626


Contacts
Contact: Assy Nimer, MD +97246828445 assy.n@ziv.health.gov.il

Locations
Israel
Liver clinic Not yet recruiting
Hedera, Israel
Contact: Saif Abu Much, MD         
Ziv medical center liver unit Not yet recruiting
Safed, Israel, Israel, 13100
Contact: Nimer Assy, MD    +972-46828445    assy.n@ziv.health.gov.il   
Sponsors and Collaborators
Ziv Hospital
Hillel Yaffe Medical Center
  More Information

Responsible Party: Liver Clinic, Ziv medical center
ClinicalTrials.gov Identifier: NCT01146626     History of Changes
Other Study ID Numbers: HCV +Vitamin D
First Submitted: June 16, 2010
First Posted: June 17, 2010
Last Update Posted: April 28, 2011
Last Verified: June 2010

Keywords provided by Ziv Hospital:
Vitamin D
Hepatitis C
Genotype2,3
SVR
Naive
RVR rate
EVR rate
SVR rate

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Vitamins
Vitamin D
Ergocalciferols
Ribavirin
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents